Oscillo Biosciences has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).
The $449,695 grant supports the development of SynchronyGamma — Oscillo's innovative music-based intervention designed to treat Alzheimer's disease and mild cognitive impairment (MCI).
The SBIR program is the U.S. government's largest source of early-stage funding for technology commercialization, and awards are highly competitive. This grant from the NIA — the lead federal agency for Alzheimer's disease research — validates both the scientific rigor and therapeutic potential of Oscillo's approach.
SynchronyGamma combines rhythmic music with precisely synchronized light stimulation to entrain theta-gamma neural activity in the brain. By leveraging the brain's natural capacity for neural resonance with musical stimuli, the intervention aims to strengthen neural oscillations, improve memory, and preserve cognitive function in individuals with early-stage Alzheimer's disease.
This funding has been instrumental in advancing Oscillo's NIH-funded clinical trial (NCT05984524), currently being conducted in partnership with the MIND Lab at Northeastern University.
The SBIR grant represents a significant milestone in Oscillo's mission to develop evidence-based, music-powered neurotherapies for neurodegenerative diseases.
Source: Oscillo Biosciences — https://oscillobiosciences.com/oscillo-biosciences-awarded-phase-i-sbir-grant-from-nih-nia/